Gastroenterology - Portugal | Statista Market Forecast

The Gastroenterology market in Portugal is expected to experience a significant increase in revenue, reaching US$304.00m in 2024.
This projection indicates a positive growth trend for the market.
Furthermore, it is anticipated that the revenue will continue to grow steadily with an annual growth rate of 2.69% from 2024 to 2029.
By the end of 2029, the market volume is projected to reach US$347.10m, showcasing the potential for expansion and development in this field.
When compared to other countries globally, it is worth noting that United States is set to generate the highest revenue in the Gastroenterology market.
In 2024 alone, United States is estimated to generate a substantial amount of revenue, reaching US$60.48bn.
This showcases the dominant position of the United States in this market.
Portugal's gastroenterology market is experiencing a surge in demand for advanced endoscopic procedures and cutting-edge diagnostic techniques.

Definition:
Gastroenterology refers to medical treatments and procedures that are provided to patients who require overnight hospitalization for digestive system disorders, e.g., gastrointestinal motility disorders, inflammatory bowel diseases, and liver diseases. Patients are provided with a variety of services during their stay in the hospital. These include endoscopic procedures (e.g., colonoscopies or upper endoscopies), surgical interventions, and changes to their diet and lifestyle that help manage the underlying condition and improve digestive health.

Additional information:
The Gastroenterology market comprises revenues and average revenue per capita. Market values represent revenues paid to hospitals by the respective healthcare payers (including VAT, if applicable). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.

Diagnostic and therapeutic endoscopic procedures
Surgical interventions for digestive system diseases
Monitoring and management of patients receiving nutrition support

Treatment of chronic digestive system diseases that do not require hospitalization
Routine follow-up care after hospitals discharge

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Inflammatory bowel disease (IBD) refers to disorders that cause chronic inflammation of the digestive tract. The two most common types of IBD are Crohn’s disease and ulcerative colitis. IBD can be difficult to diagnose because symptoms are typical of other illnesses and diseases and can vary from person to person. Symptoms of IBD include diarrhea, stomach pain and cramping, bleeding ulcers, weight loss, and fatigue. A survey of patients with Crohn's disease in North America and Europe found that 56 percent had experienced tiredness/exhaustion/fatigue in the past month, while 53 percent had abdominal pain/cramps. Such symptoms were only slightly less common among patients with ulcerative colitis.